UCLA researchers have come across an unexpected potential use for fluoxetine – commonly known as Prozac – which shows promise as an antiviral agent. The discovery could provide another tool in treating human enteroviruses that sicken and kill people in the USA and around the world.
30 July, 2012
A drug commonly used to treat immune disorders such as lymphoma and arthritis also benefits patients with an immune disorder of the kidneys that can lead to kidney failure, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN). The findings could help people who are living with the condition, called idiopathic membranous nephropathy (IMN), avoid taking the potentially toxic medications that are currently prescribed to treat it.
27 July, 2012
An interdisciplinary team of researchers from Vanderbilt University, Vanderbilt University Medical Center, the Cleveland Clinic and Meharry Medical College are creating a "microbrain bioreactor” to monitor how the human brain responds when exposed to minute quantities of dietary toxins, disease organisms or new drugs under development.
26 July, 2012
Agnieszka Gembarska and Chris Marine from VIB and the University of Leuven have found a new line of approach in which to treat these aggressive skin cancers, namely by combating the interaction between the protein MDM4 and the tumor suppressor p53. Their research offers a new angle for the development of medication and confirms that combination therapies, including those using the recently developed BRAF inhibitors, hold the promise of further improvement of the clinical response to a treatment. This study was published in the authoritative journal Nature Medicine and will undoubtedly be followed with interest by the pharmaceutical industry.
24 July, 2012
An international team of scientists, led by researchers from the Department of Pediatrics at the University of California, San Diego School of Medicine, have identified the first reported inhibitors of a key enzyme involved in survival of the parasite responsible for malaria. Their findings, which may provide the basis for anti-malarial drug development, are currently published in the online version of the Journal of Medicinal Chemistry.
23 July, 2012
Fragment methods have now become well established within the repertoire of drug discovery technologies used within the pharma and biotech industries. Success has been repeatedly demonstrated in the application of fragment methods as the basis for the discovery of drug candidates with attractive physicochemical properties for soluble protein targets.
23 July, 2012
Scientists from the Uniformed Services University of the Health Sciences (USU) have developed a new preparation method that renders a virus or bacterium non-infectious while preserving its immune-boosting ability after exposure to gamma radiation. A lethally irradiated vaccine was successfully tested in mice against drug-resistant Staphylococcus aureus bacteria by colleagues at the National Institutes of Health (NIH), and holds promise for other such deadly diseases.
18 July, 2012
Professor Sir David Lane is the recipient of this year’s Cancer Research UK Lifetime Achievement in Cancer Research Prize.
17 July, 2012
GSK launches new advertising campaign to highlight the role that science will play in keeping the London 2012 Games clean
16 July, 2012
Cancer treatments are becoming increasingly personalized, as regulators are approving therapeutics offering significant benefits to small target populations, according to a new report by healthcare experts GBI Research.
13 July, 2012
A molecular post-it note added to a breast cancer gene could flag up the risk that the disease will spread in patients, according to research published in the British Journal of Cancer.
11 July, 2012
Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT) announced that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries.
10 July, 2012
Brain Plasticity, Inc. (BPI) of California is spearheading the Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults (e-CAeSAR) clinical trial in collaboration with the National Institute of Mental Health (NIMH) to evaluate a computer-based brain-plasticity program.
03 July, 2012
The latest issue of Drug Discovery Today is packed full of industry focused research articles, new developments in drug discovery, and expert comment and opinion.
03 July, 2012
Seven of the UK’s up and coming new cancer researchers have been awarded prestigious grants by Cancer Research UK to help them on their way towards becoming tomorrow’s research leaders.
02 July, 2012